• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Journal PharmaceuticalIntelligence.com
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2022 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • SOP Web STAT
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

Joel Shertok, PhD, Member of The Board, Business Development and Process Designer of a Global AI-based External Relations Prospecting System for LPBI Group

Joel Shertok, PhD, ex-Member of The Board, ex-Business Development and Process Designer of a Global AI-based External Relations Prospecting System for LPBI Group

Affiliation with LPBI Group:

12/22/2019 – 5/4/2021

UPDATED on 11/9/2020

Selected Projects:

1. BOT-based Prospective System based on 12 Economic Segments 

Under exploration: New BOT Vendor

Opportunities Map in the Acquisition Arena

  • Prepare one prototype for industry of your choice
  • Scale up to 6 industries – get Aviva’s input in selection

2. IB communications

BIO

Dr. Joel Shertok

jshertok@processindconsultants.com  

302-562-9759

 

Dr. Joel Shertok is a senior level executive who has over 40 years of experience in the Chemical Process and Materials industries. His track record is characterized by: merger and acquisition experience, development of new product lines, creation of new business ventures, creation/motivation of new business teams, and international investigations of novel technologies.

Previously, Dr. Shertok has been a Research Fellow at Rochester Institute of Technology. He has held senior technical and managerial positions at Rochester Midland Corporation (formulated products and sanitizers, Graver Technologies (filtration and purification), Pall-Gelman Corporation (membrane filtration and water purification), Amoco Corporation (Carbon fiber composites and BioTechnology), and Union Carbide (specialty chemicals).

Dr. Shertok holds numerous patents in membrane technology, carbon purification, and in industrial food service cleaners. He is currently President of Process Industries Consultants, a chemical engineering consulting firm located in Newark, Delaware.

Curriculum Vitae

Responsibilities

Verticals:

(1) Chemical Industry

(2) Financials & Insurance: Health Care

(3) Biotech

(4) Private Equity

Business Development responsibilities @LPBI:

(1) All Documentation Artifacts expected by External Relation

(2) Client facing engagement with External relations: Information Syndication

(3) Development of a Bot-based Global Prospecting System for LPBI

3.1 applications on ALA’s 7,300

3.2 applications on JTS’s 1st degree connections on LinkedIn

(4) LPBI’s LEAD all efforts with IB

(5) LPBI’s LEAD for all Partnerships:

5.1 LPBI J-V (30%) with ABI-Lab (70%)

5.2 BurstIQ

5.3 Agreements with Wolfram Machine Learning Approach https://www.wolfram.com/featureset/machine-learning/ 

Plan for Business Development Activity at 1.0 LPBI 4Q 2020

  • 1,4,5, ABOVE

Roles on 2.0 LPBI Group’s TNS #1,2,3,4,5,6 https://pharmaceuticalintelligence.com/vision/

  • 2,3,5, ABOVE

TNS #1: See 5.3, above – TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market

TNS #2: See 5.2, above, Blockchain Transactions and broadcasting to communities in the Health Care Sector – THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: BustIQ – lined them up and are willing to build the Front End

TNS #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA

TNS #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio  [SEE New Yorker] – HAS POTENTIAL

TNS #5: See 5.1, above Joint venture with Dr. Nir for Drug Discovery: 

TNS #6:  e-Books Translations into Japanese, Spanish, Russian 

Plan for Business Development Activity at 2.0 LPBI 1Q 2021

  • See 5.1, 5.2, 5.3, above

Publications with Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Why We Can’t Foresee the Pandemic’s Long-Term Effects jshertok
COVID-19, Economic Impact of Coronavirus Pandemic, Population Health Management, Population Health Management, Genetics & Pharmaceutical, U.S. Employment-to-Population Ratio
Published
2020/07/03 at 7:20 pm
The COVID-19 Recovery will be digital: A plan for the First 90 Days jshertok
COVID-19, Economic Impact of Coronavirus Pandemic, Population Health Management, Population Health Management, Genetics & Pharmaceutical, U.S. Employment-to-Population Ratio
Published
2020/05/16 at 12:08 pm
The Impact Of The Coronavirus Crisis On Mergers And Acquisitions jshertok
COVID-19, Economic Impact of Coronavirus Pandemic, Population Health Management
Published
2020/04/17 at 9:30 am
When Will Life Be Normal Again? We Just Don’t Know jshertok
COVID-19, Economic Impact of Coronavirus Pandemic, Population Health Management
Published
2020/04/13 at 10:15 am
Economic Implications of the Coronavirus jshertok
COVID-19, Economic Impact of Coronavirus Pandemic
Published
2020/03/21 at 2:04 pm
Will the Coronavirus Permanently Change Our Way of Working? jshertok
COVID-19, Economic Impact of Coronavirus Pandemic, Population Health Management, Genetics & Pharmaceutical, Virus Infective Acute Respiratory Syndrome: SARS-CoV
Published
2020/03/19 at 2:44 pm
The Problem and Challenges of Commercialization jshertok Commercialization, Drug Development Process, Pharmacovigilance, Rapid automation of plasma protein pools Published
2019/12/23 at 1:02 pm

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to print (Opens in new window)
  • Click to email a link to a friend (Opens in new window)

Like this:

Like Loading...

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 9,459 other subscribers
  • Recent Posts

    • Creating a Twitter Space for @pharma_BI for Live Broadcasts March 14, 2023
    • The Vibrant Philly Biotech Scene: Recent Happenings & Deals March 11, 2023
    • Peak oxygen uptake (VO2peak) quantified fitness: Lifelong and late-onset athletes had higher VO2peak than non-athletes March 7, 2023
    • Merck’s sotatercept overachieves, PCSK9 inhibitor passes phase 2 March 6, 2023
    • Bacterial multidrug resistance problem solved by a broad-spectrum synthetic antibiotic March 1, 2023
    • Genetic variation causes human lupus, systemic lupus erythematosus (SLE) February 23, 2023
    • Mimicking vaginal cells and microbiome interactions on chip microfluidic culture February 14, 2023
    • Press Release for Five Bilingual BioMed e-Series in English and in Spanish January 29, 2023
    • 2022 FDA Drug Approval List, 2022 Biological Approvals and Approved Cellular and Gene Therapy Products January 17, 2023
    • Verily announced other organizational changes, 1/13/2023 January 16, 2023
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 Amandeep Kaur
    • 1 Aashir Awan, Phd
    • 1 Abhisar Anand
    • 1 Adina Hazan
    • 1 Alan F. Kaul, PharmD., MS, MBA, FCCP
    • 1 alexcrystal6
    • 1 anamikasarkar
    • 1 apreconasia
    • 1 aviralvatsa
    • 1 David Orchard-Webb, PhD
    • 1 danutdaagmailcom
    • 1 Demet Sag, Ph.D., CRA, GCP
    • 1 Dror Nir
    • 1 dsmolyar
    • 1 Ethan Coomber
    • 1 evelinacohn
    • 1 Gail S Thornton
    • 1 Irina Robu
    • 1 jayzmit48
    • 1 jdpmd
    • 1 jshertok
    • 1 kellyperlman
    • 1 Ed Kislauskis
    • 1 larryhbern
    • 1 Madison Davis
    • 1 marzankhan
    • 1 megbaker58
    • 1 ofermar2020
    • 1 Dr. Pati
    • 1 pkandala
    • 1 ritusaxena
    • 1 Rick Mandahl
    • 1 sjwilliamspa
    • 1 Srinivas Sriram
    • 1 stuartlpbi
    • 1 Dr. Sudipta Saha
    • 1 tildabarliya
    • 1 vaishnavee24
    • 1 zraviv06
    • 1 zs22

Powered by WordPress.com.

WPThemes.


 

Loading Comments...
 

    %d bloggers like this: